Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 120

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part II, Item 3
Chunk 120
---
Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Item 5. OTHER INFORMATION

Rule 10b5-1 Trading Plans

During the quarter ended March 31, 2025, no director or executive officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 52

Table of Contents

Item 6. EXHIBITS

The exhibits listed below are filed or furnished as part of this report.

Exhibit NumberDescription3.1Third Amended and Restated Bylaws. (1)10.1Settlement Agreement, dated April 7, 2025,  by and between Pacira BioSciences, Inc. and Pacira Pharmaceuticals, Inc. with Fresenius Kabi USA, LLC, eVenus Pharmaceutical Laboratories Inc., and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (f/k/a Jiangsu Hengrui Medicine Co., Ltd.).*   ††   ##10.2Amended and Restated 2014 Inducement Plan. *** (2)10.3Form of Nonstatutory Stock Option Agreement under the Amended and Restated 2014 Inducement Plan. *** (3)10.4Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2014 Inducement Plan. *** (4)31.1Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*31.2Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*32.1Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**101The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc. for the quarter ended March 31, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language):